Stable PSA levels at radiographic progression may be associated with more aggressive, AR-independent variants of prostate cancer (32), and nearly a quarter of patients in the PREVAIL trial had stable PSA levels at the time of imaging progression. The gene discussed is AR; the disease is prostate carcinoma.